This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Kenneth Mark Page: Innovator in Pharmaceutical Chemistry
Introduction
Kenneth Mark Page is a notable inventor based in Cheshire, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on amide derivatives. His research focuses on compounds that have potential therapeutic applications in treating diseases mediated by cytokines.
Latest Patents
Kenneth Mark Page holds 1 patent related to amide derivatives. The invention concerns a compound of the Formula I, wherein m is 0-2 and each R is a group such as hydroxy, halogeno, trifluoromethyl, heterocyclyl, and heterocyclyloxy. The patent also describes processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of various medical conditions.
Career Highlights
Kenneth is associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to contribute to the development of innovative therapies that address critical health challenges.
Collaborations
Throughout his career, Kenneth has collaborated with esteemed colleagues, including Paul Allen Bethel and Ian Alun Nash. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical solutions.
Conclusion
Kenneth Mark Page's contributions to pharmaceutical chemistry, particularly through his patent on amide derivatives, highlight his role as an innovator in the field. His work continues to impact the development of therapies for diseases mediated by cytokines.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile